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Pubertal Growth in Young Adult Survivors
of Childhood Leukemia
By E. Didcock, H.A. Davies, M. Didi, A.L. Ogilvy Stuart, J.K.H. Wales, and S.M. Shalet
Purpose: To determine the effect of cranial irradia-
tion (18 Gy and 24 Gy) on pubertal growth in young
adult survivors of childhood acute lymphoblastic leuke-
mia (ALL).
Patients and Methods: Final height (FH) and pubertal
growth were retrospectively examined in 142 young
adult survivors of childhood ALL. All were in first remis-
sion and had received either 18 or 24 Gy of cranial irradi-
ation. Eighty-four children (48 girls) were treated with
24 Gy and 58 (35 girls) with 18 Gy. None had received
either testicular or spinal irradiation. Timing and dura-
tion of puberty were studied in 110 patients.
Results: Significant reduction in height standard devi-
ation score (SDS) from diagnosis to FH was seen in both
sexes and in both dose groups. In girls, in both dose
groups, mean age at peak height velocity (PHV) and
A CUTE LYMPHOBLASTIC leukemia (ALL) is the
most common childhood malignancy, with an inci-
dence of 3.5 per 100,000. Survival rates for children with
ALL have improved enormously over the last 20 years,
such that 70% of children can now expect to be long-
term survivors with current therapy.', 2 Since 1970, this
has in part been achieved by the introduction of treatment
directed at the CNS, with a combination of cranial irradia-
tion and intrathecal methotrexate.3 Until 1980, the dose
of cranial irradiation given was 24 Gy (usually adminis-
tered in 15 fractions over 3 weeks). This was reduced to
18 Gy (administered in 10 fractions over 2 weeks) in
1981 in an attempt to reduce the morbidity seen with the
higher dose.
It is well recognized that higher doses of cranial irradia-
tion (21 to 24 Gy) can cause significant loss in standing
height.4-6 At lower doses, the effects on growth and, more
importantly, on final height have been less clear.68 Early
and precocious puberty in girls have also been reported
after both doses of cranial irradiation.6"9
Disproportion at final height after treatment for ALL
in childhood was recently reported by our group. This
suggests that at least in some children, much if not all of
the height loss is due to a reduction in sitting height."'
In this study, we examined the effect of both 18 Gy
and 24 Gy of cranial irradiation on growth and the timing
and duration of puberty.
PATIENTS AND METHODS
Young adult survivors of childhood ALL were identified from
three regional pediatric oncology/hematology centers. All had re-
ceived combination chemotherapy and cranial irradiation as CNS
prophylaxis. All were in first remission, and none had received either
mean age at menarche occurred significantly earlier than
in the normal population. In boys, there was a normal
timing of PHV. The amplitude of PHV was significantly
reduced in both sexes and in both dose groups. Parame-
ters of pubertal duration (PHV to menarche, PHV to FH,
and menarche to FH) were not significantly different from
normal population values.
Conclusion: In conclusion, puberty occurred early in
girls, but not in boys. Amplitude of PHV was reduced in
both sexes, with no reduction in the duration of puberty.
It is likely that disturbances of both timing and quality of
growth during puberty contribute to the loss of standing
height and body disproportion seen in these children.
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spinal or gonadal irradiation. All had achieved final height. Children
who had received growth hormone (n = 15) or sex corticosteroids
(n = 3) were excluded (all 18 had received 24 Gy). Details of
chemotherapy and radiotherapy were obtained from clinical records.
The children were divided into four groups by sex and dose of
radiotherapy received. The group 24G consisted of girls who had
received 21 to 24 Gy, and the group 24B of boys who had received
21 to 24 Gy. The groups 18G and 18B consisted of girls and boys,
respectively, who received 18 Gy of cranial irradiation. Each group
was then further divided by age at diagnosis (< or > 7 years). The
age of 7 years was arbitrarily chosen to provide a group of children
treated prepubertally in whom the pubertal growth pattern could
be evaluated, independent of any catch-up growth phenomenon. In
addition, this is the dividing age used by previous investigators 6'1
and allowed comparison of our data with theirs.
Standard chemotherapy regimens were used for all patients (eg,
United Kingdom Acute Lymphoblastic Leukaemia [UKALL] trials
I, II, III, V, VII, and VIII). These consisted of induction of remission
using three or four drugs (eg, asparaginase, vincristine, and predniso-
lone, plus one or two additional agents in UKALL X). This was
followed by a period of intensification in some, and then by a four-
drug maintainance regimen (oral methotrexate, mercaptopurine, vin-
cristine, and prednisolone). A subgroup (n = 8) received more toxic
chemotherapy (UKALL IV and VI and Memphis V), in that they
From the Department of Child Health, Queens Medical Centre,
Nottingham, University Department of Paediatrics, The Children's
Hospital, Sheffield; and Department of Endocrinology, Christie Hos-
pital, Manchester, United Kingdom.
Submitted January 9, 1995; accepted June 1, 1995.
Supported by grants from the Leukaemia Research Fund, London,
United Kingdom (M.D. and H.A.D.).
Address reprint requests to E. Didcock, BM, BS, Department of
Child Health, University Hospital, Nottingham, United Kingdom
NG7 2UH.
© 1995 by American Society of Clinical Oncology.
0732-183X/95/1310-0006$3.00/0
Journal of Clinical Oncology, Vol 13, No 10 (October), 1995: pp 2503-2507 2503
Downloaded from ascopubs.org by University of Queensland on March 16, 2017 from 130.102.082.198
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
DIDCOCK ET AL
received intravenous cyclophosphamide during both induction and
maintainance chemotherapy. This subgroup of patients were all in
the 24-Gy group. No patient received intravenous methotrexate.
All available auxologic data on each child were examined. All had
been measured serially from diagnosis using a standing height stadiome-
ter. The majority of measurements were made every 6 to 12 months,
with a few (n = 5) being a maximum of 15 months apart. Final height
(FH) was defined as height reached when the height velocity over the
preceding year was less than 1 cm/yr. Standing height standard devia-
tion score (SDS) at diagnosis and at FH were calculated using the
standards reported by Tanner et al. 2 Change in SDS was the difference
in SDS between diagnosis and FH.
Timing of puberty and growth during puberty were studied using
age at peak height velocity (PHV; mid age over which maximal
growth velocity occurred), amplitude of PHV (pubertal growth
spurt), age at menarche in girls, and age at FH. The completeness
and reliability of data related to age at onset of puberty were deemed
inadequate for inclusion in the study.
Parameters of duration of pubertal growth were calculated by
subtracting age at PHV from age at menarche, age at menarche from
age at FH, and age at PHV from age at FH. For those girls in
whom height at menarche was available (included if there was a
measurement within 2 months of the date of menarche), residual
growth from menarche to FH was calculated. Comparison with con-
temporary British normal population data was made for the parame-
ters of pubertal growth.'3
A subset of girls with early puberty (age at PHV < 10.9 years)
was identified from both dose groups. This subdivision was chosen
to allow comparison with the normal early developers identified
from the cohort of Leeds children studied by Buckler.'3
Statistics
Paired t tests were used to compare height SDS at diagnosis
with height SDS at FH. Unpaired t tests were used to compare the




One hundred forty-two children were eligible for inclu-
sion in the study. Of these 84 (60%) had received 21 to
24 Gy (48 girls and 36 boys; cranial dose 21 Gy, n = 9)
and 58 (40%) had received 18 Gy (35 girls and 23 boys).
For analysis of timing and duration of puberty, girls
older than 11 years and boys older than 13 years at diag-
nosis were excluded (11 of 142). A further 21 children
were excluded due to incomplete pubertal data. Age at
diagnosis, age at final evaluation (FH), and length of
time off therapy are listed for each of the four groups in
Table 1.
Effect on FH
FH data are reported in detail elsewhere,'" but are in-
cluded here in brief to aid description of the study popula-
tion. Significant reduction in final height SDS was seen
in both dose groups and in both sexes. Mean changes in
Table 1. ALL Groups: Age at Diagnosis, Age at Final Evaluation,
and Length of Time off Treatment
Age at Final
Evaluation
Age at Diagnosis (yr) (yr)' Time Off Therapy (yr)
Group Median Range Mean ÷ SD Median Range
18 Gy girls 6.2 2.4-10.7 14.8 + 1.0 7.2 3.3-10
18 Gy boys 8.3 1.7-12.5 17.2 _ 0.8 6.7 3.0-13.9
24 Gy girls 4.1 1.4-10.5 15.2 + 0.8 9.3 5.6-12.0
24 Gy boys 4.8 1.6-11.2 17.9 + 1.1 10.8 5.1-15.2
Abbreviation: yr, years.
*At adult height lie, when growth is < 1 cm/yr in the preceding year).
height SDS from diagnosis to final height for the 24G
and 24B groups were -1.55 and -0.9, respectively, and
for the 18G and 18B groups, -1.1 and -0.7, respectively.
In terms of actual centimeters lost, 23 (48%) of the 24G
group, 11 (31%) of the 24B group, 10 (29%) of the 18G
group, and four (17%) of the 18B group had a change in
height SDS equivalent to a loss in height of 10 cm.
Effect on Timing of Puberty
Mean age at PHV and age at menarche are listed in
Tables 2 and 3. In girls in both dose groups, PHV oc-
curred significantly earlier than in the normal population
(12.1 years) at a mean of 10.7 (P < .001) and 11.0 (P
< .001) years, respectively, for the 24G and 18G groups.
Age at menarche was also significantly earlier than the
normal population mean (13.4 years) in both dose groups
at a mean of 12.2 (P < .001) and 12.3 (P < .001) years,
respectively, for the 24G and 18G groups. Further analy-
sis by age at diagnosis demonstrated that it was only in
those patients who were younger at diagnosis (< 7 years)
in both dose groups that this difference was significant
(P = .001 and P = .0001, respectively). In boys, in both
dose groups, age at PHV was not significantly different
from normal population data (Table 3).
Effect on PHV
PHV in all four groups is listed in Tables 2 and 3. In
girls, the magnitude of PHV was not significantly differ-
ent from normal population values for girls with normal
timing of puberty. However, PHV and age at PHV are
not independent variables, with earlier onset of PHV asso-
ciated in normal children with a greater magnitude of
pubertal growth spurt (see later).
In younger girls (< 7 years), there was a reduction in
PHV when compared with girls older than 7 years at
diagnosis; this difference was statistically significant only
in the 24Gy group (P = .03).
In boys, in both dose groups, PHV was significantly
2504
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Table 2. Girls: Age at PHV, Age at Menarche, and Magnitude of PHV in 18-Gy and 24-Gy Groups, With Comparable Normal Data
Age at PHV (yr) Age at Menarche (yr) PHV (cm/yr)
Girls n Mean SD n Mean SD n Mean SD
18 Gy
Total group 22 11.0* 1.16 26 12.3* 1.3 22 8.1 1.07
< 7 years at diagnosis 14 10.4t 0.7 15 11.7t 0.74 14 7.9 1.07
> 7 years at diagnosis 8 12.1 0.7 11 13.1 0.78 8 8.9 1.4
24 Gy
Total group 42 10.7* 1.06 39 12.2* 0.8 42 7.8 1.2
< 7 years at diagnosis 36 10.5 0.9 34 12.1 t 0.9 36 7.41 1.15
> 7 years at diagnosis 6 11.6 1.2 5 12.7 0.3 6 8.8 1.1
Normal population 102 12.1 0.98 102 13.4 1.1 102 8.1 1.07
*Group mean significantly different from population mean.
tMean of group < 7 years at diagnosis significantly different from mean of group > 7 years at diagnosis.
less than normal population values (P < .001 and P <
.05, for 24B and 18B, respectively).
Effect on Duration of Puberty
The mean interval from age at PHV to age at FH was
not significantly reduced in either girls (Table 4) or boys.
Indeed, in the 24G and 24B groups, it appeared to be
significantly longer than normal population values (P <
.001 and P < .01, respectively). Age at PHV to age at
menarche, and age at menarche to age at FH, are also
listed in Table 4.
Growth in Early-Developing Girls
Table 5 lists data for girls in both dose groups whose
age at PHV was less than 10.9 years compared with nor-
mal data.' 3 Mean PHV was significantly reduced at 7.7
and 7.9 cm/yr for the 24G (P < .001) and 18G (P < .01)
groups when compared with the normal early-developing
girls (9.01 cm/yr). Girls in both dose groups also had
significantly less growth after menarche (mean, 5.8 cm
Table 3. Boys: Age at PHV and Magnitude of PHV in 18-Gy and 24-Gy
Groups, With Comparable Normal Data
Age at PHV (yr) PHV (cm/yr)
Boys n Mean SD n Mean SD
18 Gy
Total group
< 7 years at diagnosis
> 7 years at diagnosis
24 Gy
Total group
< 7 years at diagnosis

























Normal population 216 14.1 1.0 216 9.8 1.2
*Group mean significantly different from population mean.
6.2 cm, respectively, for 24G [P < .01] and 18G [P < .02]
groups, compared with 8.6 cm in the normal population).
In the 24G group, PHV to menarche was significantly
longer than in the normal group (P < .001), with the time
from menarche to FH being significantly shorter (P <
.01). PHV to FH was not significantly different between
the groups.
DISCUSSION
Data on growth and pubertal disturbance following
treatment for childhood ALL are conflicting.4 7 Treatment
variables, particularly differences in chemotherapy sched-
ules and variation in total dose and fractionation of cranial
irradiation, may account for some of the discrepancies.
In addition, it is only recently that sufficient long-term
survivors have reached adulthood to allow the final im-





We have previously reported a loss in standing height
at FH after both 18 Gy and 24 Gy of cranial irradiation
that is of a similar magnitude to that reported by previous
investigators.68,'10,14 Much of this height loss is due to
body disproportion, ie, a loss in sitting height."' In this
study, we have examined pubertal growth in an attempt
to explain this disproportion, as much of normal spinal
growth occurs during puberty.
We have shown that in girls less than 7 years of age
at diagnosis, both PHV and menarche occur significantly
earlier than normal. Early onset of puberty was also ob-
served in girls less than 7 years of age at diagnosis by
Ureuna et al,6 with earlier onset of puberty correlating
with the lower dosage of irradiation. In contrast, other
investigators have found normal timing of puberty in their
study groups.",' 5 Both of the latter studies include only
small numbers at FH.
In boys, we report normal timing of PHV. We do not
have sufficient data to comment on the onset of puberty
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Table 4. Girls: Interval Between Stages of Puberty, and Magnitude of Height Increment From Menarche to FH, With Comparable Normal Data
Age at PHV to Age at Age at Menarche to Age at
Menarche (yr) FH (yr) Age at PHV to Age at FH (yr) Menarche to FH (cm)
Girls n Mean SD n Mean SD n Mean SD n Mean SD
18 Gy
Total group 19 1.3 0.76 19 2.65 0.82 19 3.95 1.18 18 6.03 2.3
< 7 years at diagnosis 12 1.55 0.72 12 2.9 0.72 13 4.18 1.18 9 7.1 1.7
> 7 years at diagnosis 7 0.88 0.66 8 2.2 0.9 6 3.47 1.13 9 4.9 2.4
24 Gy
Total group 35 1.65* 1.0 35 2.98 0.95 41 4.56* 1.04 24 6.46 3.7
< 7 years at diagnosis 30 1.73 1.03 30 3.04 1.0 35 4.68 0.96 20 6.45 3.9
> 7 years at diagnosis 5 1.16 1.11 5 2.6 0.42 6 3.9 1.33 4 6.5 2.3
Normal population 98 1.23 0.56 76 2.71 1.18 77 3.97 1.03 78 6.1 2.6
*Group mean significantly different from population mean.
in our group, but suspect that there is normal harmony
in the sequence of the acquisition of secondary sexual
characteristics and the relation of these to the growth
spurt, as in a similar cohort of irradiated boys.9 A trend
toward earlier onset of puberty in boys was reported by
Ureuna et al,6 but this was not significantly different from
normal population data. Hokken-Koelega et al" used life-
tables to analyze pubertal onset in boys, and found this
to be similar, to nonirradiated children.
Other investigators have shown the magnitude of the
growth spurt in girls who have received both 18 and 24
Gy to be significantly less than in nonirradiated girls.9,14-16
In our study, we have shown that the group as a whole
did not show a reduction in PHV, but that there was no
compensatory increase in PHV in the early-developing
girls as occurs in nonirradiated early developers. The
greatest reduction also occurs in those who were younger
at irradiation.
Few data are available in boys. Hokken-Koelega et al"t
reported a reduction in PHV in irradiated boys, although
only four subjects in this study had reached FH. Ureuna
et al6 also reported a reduction in height SDS in both 18-
and 24-Gy groups during puberty, although they did not
comment on PHV. In our series, PHV was reduced in
boys in both dose groups, with a trend to a greater reduc-
tion in boys who were younger at diagnosis. As in previ-
ous studies, the number of boys older than 7 years at
diagnosis who received 18 Gy is small. Also, catch-up
growth after completion of treatment may have interfered
with assessment of PHV in those who were older at diag-
nosis, in both sexes.
Duration of puberty has not been studied thoroughly
in adult survivors of childhood leukemia, although a re-
duction in the length of pubertal growth might be ex-
pected to contribute to the body disproportion seen in
these patients. Quigley et a117 have shown a reduction in
the interval between thelarche and menarche of approxi-
mately 1 year in a small number of girls (n = 8) treated
with 24 Gy. We have shown no such reduction, but clearly
these results must be interpreted with caution, as they do
not include complete data on pubertal duration. Also, the
comparative normal data set used in this study may in-
clude a proportion of children who were not strictly at
FH, ie, with continued late adolescent growth." This may
explain the apparently longer duration of PHV to FH seen
in both girls and boys who had received 24 Gy.
Considerable controversy exists over the biologic con-
tribution of radiation-induced growth hormone deficiency
to growth, particularly during puberty. Reduced spontane-
ous growth hormone secretion during 24-hour profiles
has been described in both prepubertal and pubertal girls
following 24 Gy of cranial irradiation, with a failure of
Table 5. Girls: Early Developers (age at PHV < 10.9 years)-1 8-Gy and 24-Gy Groups, With Comparable Normal Data
PHV to Menarche (yr) Menarche to FH (yr) PHV to FH (yrs) Menarche to FH (cm) PHV (cm/yr) Age at Menarche (yr)
Girls n Mean SD n Mean SD n Mean SD n Mean SD n Mean SD n Mean SD
18 Gy* 12 1.5 0.7 14 2.7t 0.9 11 4.4 1.2 11 6.2t 2.6 11 7.9t 1.1 12 11.7 0.8
24Gy* 23 2.1t 1.0 24 3.11t 0.9 27 5.0 0.9 14 5.8t 3.1 27 7.7t 1.1 23 12.1 0.7
Normal population 20 1.1 0.5 15 3.7 1.1 15 4.7 1.1 16 8.6 2.3 20 9.0 0.6 20 12.0 0.5
"All ages at diagnosis.
tGroup mean significantly different from population mean.
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the expected increase in growth hormone production at
puberty, associated with an attenuated growth spurt.18
After 18 Gy, physiologic growth hormone secretion was
shown to be normal in prepuberty, with an abnormality of
periodicity and quantitative reduction in growth hormone
secretion seen only during puberty.19 Chemotherapy also
appears to be a factor in growth disturbance 4' 8, 20 and al-
most certainly contributes to reduction in FH.
In conclusion, we have shown impairment of pubertal
growth in both sexes, with early onset of puberty in girls.
The growth impairment may in part be accounted for by
abnormalities of growth hormone production, although
this does not explain the body disproportion seen in these
patients. In addition, the disproportion cannot be ex-
plained by a reduction in duration of puberty, although
this requires further study. A direct effect of chemother-
apy on the spinal epiphyses may contribute.
The etiology of standing height loss after treatment for
childhood leukemia is complex and multifactorial. Our
study supports the suggestion that those most likely to be
affected are girls who are youngest at diagnosis.
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